Apolipoprotein A-I

"Apolipoprotein A-I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.

Descriptor ID	D016632
MeSH Number(s)	D10.532.091.200.100 D12.776.070.400.200.100 D12.776.521.120.200.100
Concept/Terms	Apolipoprotein A-I Apolipoprotein A-I Apolipoprotein A I Apo A-I Apo A1 Apolipoprotein AI ApoA-1 ApoA-I Apolipoprotein A-1 Apolipoprotein A 1 Apolipoprotein A1 Apo A-1 Apo AI Pro-Apolipoprotein A-I Pro-Apolipoprotein A-I Pro Apolipoprotein A I Pro-Apo A-I Pro Apo A I Proapolipoprotein AI Apolipoprotein AI Propeptide Apolipoprotein A-I Isoproteins Apolipoprotein A-I Isoproteins Apolipoprotein A I Isoproteins Apo A-I Isoproteins Apo A I Isoproteins Apolipoprotein A-I Isoprotein-2 Apolipoprotein A-I Isoprotein-2 Apolipoprotein A I Isoprotein 2 Apolipoprotein A-I Isoprotein-4 Apolipoprotein A-I Isoprotein-4 Apolipoprotein A I Isoprotein 4

Below are MeSH descriptors whose meaning is more general than "Apolipoprotein A-I".

Chemicals and Drugs [D]
Lipids [D10]
Lipoproteins [D10.532]
Apolipoproteins [D10.532.091]
Apolipoproteins A [D10.532.091.200]
Apolipoprotein A-I [D10.532.091.200.100]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Apoproteins [D12.776.070]
Apolipoproteins [D12.776.070.400]
Apolipoproteins A [D12.776.070.400.200]
Apolipoprotein A-I [D12.776.070.400.200.100]
Lipoproteins [D12.776.521]
Apolipoproteins [D12.776.521.120]
Apolipoproteins A [D12.776.521.120.200]
Apolipoprotein A-I [D12.776.521.120.200.100]

Below are MeSH descriptors whose meaning is related to "Apolipoprotein A-I".

Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein A-I".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Apolipoprotein A-I" by people in this website by year, and whether "Apolipoprotein A-I" was a major or minor topic of these publications.

Bar chart showing 18 publications over 13 distinct years, with a maximum of 4 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	1	0	1
1999	1	0	1
2000	1	0	1
2005	0	1	1
2006	0	1	1
2008	2	1	3
2011	1	0	1
2015	0	1	1
2017	1	0	1
2018	0	1	1
2022	0	1	1
2024	4	0	4

Below are the most recent publications written about "Apolipoprotein A-I" by people in Profiles.

Gibson CM, Duffy D, Bahit MC, Chi G, White H, Korjian S, Alexander JH, Lincoff AM, Heise M, Kingwell BA, Nicolau JC, Lopes RD, Cornel JH, Lewis BS, Vinereanu D, Goodman SG, Bode C, Steg PG, Libby P, Sacks FM, Bainey KR, Ridker PM, Mahaffey KW, Aylward P, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA. Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial. Eur Heart J. 2024 12 16; 45(47):5023-5038.

View in: PubMed
Gibson CM, Chi G, Duffy D, Bahit MC, White H, Korjian S, Alexander JH, Lincoff AM, Anschuetz G, Girgis IG, Nicolau JC, Lopes RD, Cornel JH, Bainey KR, Libby P, Sacks FM, Ridker PM, Goodman SG, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights?From the AEGIS-II Trial. J Am Coll Cardiol. 2024 Nov 26; 84(22):2185-2192.

View in: PubMed
Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, Harrington RA. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction. N Engl J Med. 2024 05 02; 390(17):1560-1571.

View in: PubMed
Povsic TJ, Korjian S, Bahit MC, Chi G, Duffy D, Alexander JH, Vinereanu D, Tricoci P, Mears SJ, Deckelbaum LI, Bonaca M, Ridker PM, Goodman SG, Cornel JH, Lewis BS, Parkhomenko A, Lopes RD, Aylward P, Lincoff AM, Heise M, Sacks F, Nicolau JC, Merkely B, Trebacz J, Libby P, Nicholls SJ, Pocock S, Bhatt DL, Kastelein J, Bode C, Mahaffey KW, Steg PG, Tendera M, Bainey KR, Harrington RA, Mehran R, Duerschmied D, Kingwell BA, Gibson CM. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors?of Acute MI. J Am Coll Cardiol. 2024 Jun 04; 83(22):2163-2174.

View in: PubMed
Kalayci A, Gibson CM, Ridker PM, Wright SD, Kingwell BA, Korjian S, Chi G, Lee JJ, Tricoci P, Kazmi SH, Fitzgerald C, Shaunik A, Berman G, Duffy D, Libby P. ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. Curr Atheroscler Rep. 2022 07; 24(7):585-597.

View in: PubMed
Gibson CM, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, Tricoci P, Alexander JH, Kastelein JJP, Mehran R, Bode C, Lewis BS, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo DJ, Duerschmied D, Ophuis TO, Merkely B. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2019 02; 208:81-90.

View in: PubMed
Dunbar RL, Movva R, Bloedon LT, Duffy D, Norris RB, Navab M, Fogelman AM, Rader DJ. Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial. Clin Transl Sci. 2017 Nov; 10(6):455-469.

View in: PubMed
Joseph P, Pare G, Wallentin L, Connolly S, Yusuf S, Wang J, Ezekowitz M, Eikelboom J, Siegbahn A, Reilly P, Themeles E, Oldgren J. Dabigatran etexilate and reduction in serum apolipoprotein B. Heart. 2016 Jan; 102(1):57-62.

View in: PubMed
Nijstad N, de Boer JF, Lagor WR, Toelle M, Usher D, Annema W, der Giet Mv, Rader DJ, Tietge UJ. Overexpression of apolipoprotein O does not impact on plasma HDL levels or functionality in human apolipoprotein A-I transgenic mice. Biochim Biophys Acta. 2011 Apr; 1811(4):294-9.

View in: PubMed
Millar JS, Duffy D, Gadi R, Bloedon LT, Dunbar RL, Wolfe ML, Movva R, Shah A, Fuki IV, McCoy M, Harris CJ, Wang MD, Howey DC, Rader DJ. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan; 29(1):140-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement